Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
Department of Pharmacy, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
Int J Antimicrob Agents. 2023 Oct;62(4):106933. doi: 10.1016/j.ijantimicag.2023.106933. Epub 2023 Jul 25.
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is increasingly being identified in children, but data on the clinical outcomes in this population are limited. This study aimed to characterise the risk factors for 30-day mortality with CRKP bloodstream infection (BSI) in children.
A retrospective study was performed from January 2018 to December 2021 at the First Affiliated Hospital of Zhengzhou University. Patients aged < 18 years and with CRKP BSI were included. Multivariable Cox and logistic regression were performed to determine risk factors for death and the development of septic shock following CRKP infection, respectively.
This study identified 33 neonates aged 0-4 weeks and 37 older children. The 30-day mortality rate was 39.4% in neonates and 43.2% in older children. In the neonatal population, a higher Pitt bacteremia score (HR 1.694; 95% CI 1.313-2.186; P < 0.001) was an independent risk factor for 30-day mortality. In the non-neonatal population, higher platelet count (HR 0.990; 95% CI 0.982-0.998; P = 0.010), the use of carbapenems (HR 0.212; 95% CI 0.064-0.702; P = 0.011) and appropriately targeted antimicrobial treatment (HR 0.327; 95% CI 0.111-0.969; P = 0.044) were associated with decreased 30-day mortality. Monocyte count < 0.1 × 10 cells/L (OR 3.615; 95% CI 1.165-11.444; P = 0.026) and a higher Pitt bacteremia score (OR 1.330; 95% CI 1.048-1.688; P = 0.019) were identified as risk factors for the development of septic shock.
Carbapenem-resistant Klebsiella pneumoniae BSI was associated with high mortality in children. Appropriate antimicrobial treatment is important to improve survival, but more work is needed to assess the efficacy of specific treatment regimens in children.
耐碳青霉烯类肺炎克雷伯菌(CRKP)在儿童中越来越多地被发现,但有关该人群临床结局的数据有限。本研究旨在描述儿童耐碳青霉烯类肺炎克雷伯菌血流感染(BSI)30 天死亡率的相关危险因素。
本回顾性研究于 2018 年 1 月至 2021 年 12 月在郑州大学第一附属医院进行,纳入年龄<18 岁且患有耐碳青霉烯类肺炎克雷伯菌 BSI 的患者。采用多变量 Cox 和 logistic 回归分别确定 CRKP 感染后死亡和发生感染性休克的危险因素。
本研究纳入 33 名 0-4 周龄的新生儿和 37 名大龄儿童。新生儿的 30 天死亡率为 39.4%,大龄儿童的 30 天死亡率为 43.2%。在新生儿人群中,较高的 Pitt 菌血症评分(HR 1.694;95%CI 1.313-2.186;P<0.001)是 30 天死亡率的独立危险因素。在非新生儿人群中,较高的血小板计数(HR 0.990;95%CI 0.982-0.998;P=0.010)、使用碳青霉烯类药物(HR 0.212;95%CI 0.064-0.702;P=0.011)和适当靶向的抗菌治疗(HR 0.327;95%CI 0.111-0.969;P=0.044)与降低 30 天死亡率相关。单核细胞计数<0.1×10 细胞/L(OR 3.615;95%CI 1.165-11.444;P=0.026)和较高的 Pitt 菌血症评分(OR 1.330;95%CI 1.048-1.688;P=0.019)被确定为发生感染性休克的危险因素。
耐碳青霉烯类肺炎克雷伯菌 BSI 与儿童死亡率较高相关。适当的抗菌治疗对于提高生存率很重要,但仍需进一步研究以评估特定治疗方案在儿童中的疗效。